Create issue ticket

723 Possible Causes for 90, Lym 1, MOAB, Y, yttrium

Show results in: Română

  • Liver Metastasis

    Kinoshita K 1, 2 , Beppu T 1, 2 , Miyata T 1 , Kuramoto K 1, 2 , Yoshida Y 1, 2 , Umesaki N 1 , Kitano Y 1 , Nakagawa S 1 , Okabe H 1 , Nitta H 1 , Imai K 1 , Hayashi H 1[ncbi.nlm.nih.gov] Abstract This critical review aims to explore predictive and prognostic biomarkers of Yttrium-90 (Y90) radioembolization therapy of colorectal liver metastases.[ncbi.nlm.nih.gov] IV factor 9.09 1 0.0026 * 2.412 0.831-7.004 0.105 New drugs 0.27 1 0.6011 LN dissection 1.08 1 0.2991 Tumor size 0.03 1 0.8578 R 0.12 1 0.7309 M1(LYM) 0.99 1 0.3196 Liver[omicsonline.org] This has changed markedly since the year 2000, with the approvals of irinotecan, oxaliplatin, and three humanized monoclonal antibodies (MoAbs) that target vascular endothelial[bead.btg-im.com] Sakamoto K 1 , Honda G 2 , Beppu T 3 , Kotake K 4 , Yamamoto M 5 , Takahashi K 2 , Endo I 6 , Hasegawa K 7 , Itabashi M 5 , Hashiguchi Y 8 , Kotera Y 5 , Kobayashi S 9 , Yamaguchi[ncbi.nlm.nih.gov]

  • Malignant Neoplasm

    Ten of these 26 patients are disease free at a median of 7.7 years (range 1 to 15 y) after the last treatment.[ncbi.nlm.nih.gov] Liver-directed therapies such as radiofrequency ablation, transarterial embolization, yttrium-90 microsphere radioembolization, and cryoablation may help to shrink tumors[clinicaltrials.ucsf.edu] Association of Central Cancer Registries (which are reported in detail for the first time here and include high-quality data from 45 states and the District of Columbia, covering 90%[ncbi.nlm.nih.gov] Three types of lasers are used to treat cancer: carbon dioxide (CO 2 ) lasers, argon lasers, and neodymium: yttrium -aluminum-garnet (Nd:YAG) lasers.[cancer.gov] Only 5-10% of all cancer cases can be attributed to genetic defects, whereas the remaining 90-95% have their roots in the environment and lifestyle.[ncbi.nlm.nih.gov]

    Missing: Lym 1 MOAB
  • Follicular Lymphoma

    , Yamasaki R 1 , Kawasaki Y 1 , Sugimoto M 1 , Ashizawa M 1 , Yamamoto C 1 , Hatano K 1 , Sato K 1 , Oh I 1 , Ohmine K 1 , Muroi K 1 , Kanda Y 2 .[ncbi.nlm.nih.gov] Abstract Yttrium 90 ((90)Y) ibritumomab tiuxetan (Zevalin), a radiolabeled monoclonal antibody against the CD20 antigen, is indicated for the treatment of patients with relapsed[ncbi.nlm.nih.gov] PURPOSE: We conducted an international, randomized, phase III trial to evaluate the efficacy and safety of consolidation with yttrium-90 ((90)Y)-ibritumomab tiuxetan in patients[ncbi.nlm.nih.gov] The MoAb trials included CHOP followed by rituximab (SWOG 9800) and CHOP followed by (131)I-tositumomab (SWOG 9911).[ncbi.nlm.nih.gov] Radioisotopes/adverse effects Yttrium Radioisotopes/therapeutic use Substances Antibodies, Monoclonal Yttrium Radioisotopes Rituximab ibritumomab tiuxetan Vidarabine fludarabine[ncbi.nlm.nih.gov]

    Missing: Lym 1
  • Waldenstrom Macroglobulinemia

    Hunter ZR, Xu L, Yang G, Zhou Y, Liu X, Cao Y, Manning RJ, Tripsas C, Patterson CJ, Sheehy P, Treon SP.[ghr.nlm.nih.gov] . : Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory lowgrade[doi.org] For example, a 5-year survival rate of 90% means that an estimated 90 out of 100 people who have that cancer are still alive 5 years after being diagnosed.[cancer.org] Immunophenotypic analysis was based on the use of the triple or quadruple monoclonal antibody (MoAb) combinations.[ncbi.nlm.nih.gov] Treating Patients With Multiple Myeloma or Other B-cell Cancers Unknown status NCT00003163 Phase 2 cyclophosphamide;melphalan 48 Rituximab, Fludarabine, Cyclophosphamide, and Yttrium[malacards.org]

    Missing: Lym 1
  • IgG4-Related Hepatopathy

    Kamisawa T, Funata N, Hayashi Y, Eishi Y, Koike M, Tsuruta K et al (2003) A new clinicopathological entity of IgG4-related autoimmune disease.[link.springer.com] Xipamid X-linked SCID [D81.2] XLP [D82.3] XLPP Xylose-Toleranz-Test QR-Code: Y Y-Bypass YEL-AND YEL-AVD Yersinia enterocolitica Yersiniose [A04.6] Y-Roux-Rekonstruktion Yttrium-Ibritumomab-Tiuxetan[docplayer.net] […] dense lym-phoplasmacytic infiltrate (Figures 1 and 2), 2) fibrosis (Figures 1and 3), arranged at least focally in a storiform pattern (Figures 2and 3) obliterative phlebitis[documents.tips] […] lei Anticorpi anti influenza A IgA (INAAE) 90 lei Anticorpi anti influenza A IgG (INAGE) 90 lei Anticorpi anti influenza B (INFBK) 100 lei Anticorpi anti influenza B IgA[as-medica.ro] Semin Liver Dis 2016 Aug;36(3):229-41 PMID:27466793 查看当期期刊 Nakanuma Y,Ishizu Y,Zen Y,Harada K,Umemura T Department of Internal Medicine, Shinshu University Graduate School[paper.medlive.cn]

    Missing: MOAB
  • Desmoplastic Small Round Cell Tumor

    The 2-y and 5-y OS were 72% and 19%. The 2-y and 5-y disease-free survival (DFS) were 30% and 12%.[ncbi.nlm.nih.gov] Yttrium microspheres have been used successfully to treat liver metastasis from DSRCT.[ncbi.nlm.nih.gov] […] unusual immunohistochemical profile, including absence of significant cytokeratin expression, complete negativity for desmin and widespread loss of nuclear INI-1 expression ( 90%[ncbi.nlm.nih.gov] The gene product, a cell membrane protein, is recognized by monoclonal antibody (MoAb) HBA-71 and MoAb 12E7 and RFB-1. [5] Although a sensitive marker, MIC2 is not specific[jcytol.org] RESULTS: In this study cohort of 20 patients, median age at presentation was 29 y (range 18-43) and 90% were male. Fifty-five percent presented with metastasis.[ncbi.nlm.nih.gov]

    Missing: Lym 1
  • Intrahepatic Cholangiocarcinoma

    Another clear advantage of Y-90 radioembolization is the excellent tolerance of the therapy and low toxicity.[interventionalnews.com] In particular, radioembolization with Yttrium-90 ( 90 Y)-labeled spheres has been reported to be a promising therapeutic approach for this neoplasia.[ncbi.nlm.nih.gov] Therefore, the use of yttrium-90 microspheres should be considered in the list of available treatment options for ICC.[crukcambridgecentre.org.uk] Kumamoto T 1 , Tanaka K , Takeda K , Nojiri K , Mori R , Taniguchi K , Matsuyama R , Ueda M , Sugita M , Ichikawa Y , Nagashima Y , Endo I .[ncbi.nlm.nih.gov] INTRODUCTION: To investigate prognostic factors in unresectable intrahepatic cholangiocarcinoma (ICC) therapy-naïve patients after yttrium-90 (Y-90) radioembolization (RE)[ncbi.nlm.nih.gov]

    Missing: Lym 1 MOAB
  • Lymphoproliferative Disorder

    Kasahara H 1 , Mori T 1 , Kato J 1 , Koda Y 1 , Kohashi S 1 , Kikuchi T 1 , Sakurai M 1 , Yamane Y 1 , Mikami S 2 , Kameyama K 2 , Takahashi Y 3 , Okamoto S 1 .[ncbi.nlm.nih.gov] […] monoclonal antibodies, anti-B-cell antibodies linked to radionuclides such as tositumomab (anti-CD20 linked to iodine-131) and ibritumomab tiuxetan (anti-CD20 linked to yttrium[nature.com] Despite the use of steroids (50 mg daily), the WBC was comprised principally of lym- phocytes. His chemistry and liver function tests were Figure 1.[dx.doi.org] A serum tacrolimus level over 11.1 ng/mL was predictive of post PTLD survival (sensitivity 90%, specificity 52%, area under the curve 0.738, P 0.035).[ncbi.nlm.nih.gov] Shi X 1, 2, 3 , Ba R 1 , You H 1 , Jiang Q 1 , Huang J 4 , Mao J 3 , Han L 1 , Zhang S 1 , Zhuang Q 1 , Yu X 1 , Wang L 1 , Wang Y 1 , Li D 1 , Zhu W 5 , Zhang Y 6 , Zhu Y[ncbi.nlm.nih.gov]

    Missing: MOAB
  • ALK-Negative Anaplastic Large-Cell Lymphoma

    Honda, Y. Sadahira, Y. Suetugu, M.[scirp.org] Pralatrexate, anti-CD30 monoclonal antibodies, brentuximab vedotin (SGN-35) in particular, (131)I-anti-CD45 radioantibody, yttrium-anti-CD25 radioimmunoconjugates, histone[ncbi.nlm.nih.gov] Pediatr Hematol Oncol. 2012 Nov;29(8):686-90. doi: 10.3109/08880018.2012.725238. Epub 2012 Sep 26.[ncbi.nlm.nih.gov] Manhattan, Marathon, Maryland, Massachusetts, Memphis, Menlo Park, Mesa, Mexico City, Miami Beach, Miami, Michigan, Milwaukee, Minneapolis, Minnesota, Mississippi, Missouri, Moab[maria-online.com] Although clinically aggressive, ALK-positive tumors respond well to standard interventions, with five-year overall survival rates of about 90 percent.[mayoclinic.org]

    Missing: Lym 1
  • Plasmablastic Lymphoma

    In the reported series, PBL patients were predominantly male (77%) with a median age at diagnosis of 46 years (range, 1.2 to 87 y).[ncbi.nlm.nih.gov] […] show a greater degree of nuclear pleomorphism andmay contain more prominent nucleoli (fig 1).[docmh.com] At a median follow-up period of 42 months, the estimated 2-year progression-free and overall survival rates were 90% and 100%, respectively.[ncbi.nlm.nih.gov] Manhattan, Marathon, Maryland, Massachusetts, Memphis, Menlo Park, Mesa, Mexico City, Miami Beach, Miami, Michigan, Milwaukee, Minneapolis, Minnesota, Mississippi, Missouri, Moab[maria-online.com] The overall response rate to bortezomib-containing regimens was 100% in the frontline setting and 90% in the relapsed setting.[ncbi.nlm.nih.gov]

    Missing: yttrium